P Cavaco
7 Papers
1 Citations
P Cavaco is an academic researcher. The author has contributed to research in topics: Pharmacist & Pharmacovigilance. The author has an hindex of 2, co-authored 7 publications.
Chat about Author
Papers
Hospital pharmacist interventions in a central hospital
F Falcão,E Viegas,Carla Lopes,Rita Branco,Ana Parrinha,Marina Lobo Alves,Filipa Leal,Vanessa Pina,Brenda Madureira,P Cavaco,Sofia Santos,Sandra Carreira +11 more
TL;DR: Pharmacists’ recommendations entered in the electronic prescribing system with a short explanation are immediately available to the doctor, however, the relatively low acceptance rate suggests that a further study also evaluating verbal interventions is needed, since the most urgent recommendations are made verbally, and this would likely increase the acceptance rate.
15
Clinical Communication Within Hospital Pharmacy Practice: Exploring Pharmaceutical Oncological Consultations
TL;DR: In this paper, a cross-sectional design was used to investigate the pharmacist-patient exchange, applying the Roter Interaction Analysis System (RIAS) to identify communication trends typical of pharmacists' clinical communication in the context of hospital consultations.
4
5PSQ-064 Intensive monitoring of afatinib – case report
TL;DR: The early approval of drugs that covers therapeutic gaps reveals the necessity to implement effective and systematic methodologies that allow the surveillance of their use.
1
PS-099 Drug-drug interactions in fluoropyrimidines-based regimens used in colorectal cancer treatment
TL;DR: Evaluating drug interactions in patients with colorectal cancer who started chemotherapy between January and March 2014, in a central hospital, and who were also prescribed other drugs found dexamethasone and fluorouracil had the highest number of interactions.
Estudo de avaliação do consumo de recursos hospitalares associados à administração de trastuzumab
Sofia Andrade,Ana Luisa Santos,Aldiro Magano Magano,Alexandra Madureira,Ana Vinagre,Carlos Góis,F Falcão,Graça André,Inês Lima,Maria José Alves,Maria Nazaré Rosado,P Cavaco,Paula Rolim,Rita Lopes +13 more
- 26 Mar 2014
TL;DR: The substitution of trastuzumab IV for the SC formulation would allow a saving of about €584 per patient per year of treatment, which is undervalued due to lack of information on other costs, including costs spent by the patient.